Abstract:Purpose: Lapatinib is a dual EGFR and HER2 inhibitor that is used to treat HER2-overexpressing cancers. However, its poor water solubility hinders its clinical use. Proteobionics is a promising way to solve this problem.Methods: Lapatinib-incorporated core-shell nanoparticles (LTNPs) were prepared and characterized by cryo-transmission electron micrograph. Then, in vitro cellular uptake and in vivo glioma targeting effect were determined by both qualitative and quantitative studies. After that, anti-glioma effect of LTNPs was determined by cytotoxicity and life-span study. Finally, the mechanism was elucidated by western blot. Results: LTNPs elevated the water solubility of the drug from 0.007 mg/mL to over 10 mg/mL, which was better than most commercially available injection solvents. Glioma is an increasing threat to humans' health. Here, we evaluated the treatment effects of LTNPs on glioma and explored their mechanism. LTNPs were taken up by U87 cells, inhibiting their proliferation and causing a G2 phase arrest. The uptake was energy-, time- and concentration-dependent, and several pathways were involved. LTNPs inhibited the phosphorylation of the survival (phosphatidylinositol 3-kinase/Akt) pathways, which caused the antiproliferative effect. In vivo experiments determined that LTNPs were distributed to and accumulated in glioma by the enhanced permeation and retention effect. The distribution was colocalized with SPARC expression, which may mediate endocytosis. In pharmacokinetics and glioma distribution study, LTNPs displayed a higher blood AUC, glioma concentration and glioma/brain ratio than Tykerb. A pharmacodynamics study confirmed that LTNPs could significantly expand the median survival time of glioma-bearing mice at a cumulative dose of 40 mg/kg, which was only 5% of the dose of the commercially available lapatinib tablet (Tykerb).Conclusion: LTNPs effectively increased the solubility of lapatinib and improved the treatment of glioma. (C) 2013 Elsevier B.V. All rights reserved.

Incorporation of Lapatinib into Human Serum Albumin Nanoparticles with Enhanced Anti-Tumor Effects in HER2-positive Breast Cancer.

Incorporation of Lapatinib into Lipoprotein-Like Nanoparticles with Enhanced Water Solubility and Anti-Tumor Effect in Breast Cancer.

Lapatinib-incorporated Lipoprotein-Like Nanoparticles: Preparation and a Proposed Breast Cancer-Targeting Mechanism

Lapatinib-loaded Human Serum Albumin Nanoparticles for the Prevention and Treatment of Triple-Negative Breast Cancer Metastasis to the Brain

Incorporation of Lapatinib into Core-Shell Nanoparticles Improves Both the Solubility and Anti-Glioma Effects of the Drug

Novel Nanosystem to Enhance the Antitumor Activity of Lapatinib in Breast Cancer Treatment: Therapeutic Efficacy Evaluation.

Enhanced antitumor activity of lapatinib against triple-negative breast cancer via loading in human serum albumin

In vivo behavior and safety of lapatinib-incorporated lipid nanoparticles.

Behavior and anti-glioma effect of lapatinib-incorporated lipoprotein-like nanoparticles.

Human Serum Albumin Nanoparticulate System with Encapsulation of Gefitinib for Enhanced Anti-Tumor Effects in Non-Small Cell Lung Cancer

Glycol chitosan stabilized nanomedicine of lapatinib and doxorubicin for the management of metastatic breast tumor

A Novel Combined Micellar System of Lapatinib and Paclitaxel with Enhanced Antineoplastic Effect Against Human Epidermal Growth Factor Receptor-2 Positive Breast Tumor in Vitro

Acid-Labile Polysaccharide Prodrug Via Lapatinib-Sensitizing Effect Substantially Prevented Metastasis And Postoperative Recurrence Of Triple-Negative Breast Cancer

A novel localized co-delivery system with lapatinib microparticles and paclitaxel nanoparticles in a peritumorally injectable in situ hydrogel

Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) Against HER-2-overexpressing and Trastuzumab-Treated Breast Cancer Cells.

Specific drug delivery efficiently induced human breast tumor regression using a lipoplex by non-covalent association with anti-tumor antibodies

Lapatinib-loaded Acidity-Triggered Charge Switchable Polycarbonate-Doxorubicin Conjugate Micelles for Synergistic Breast Cancer Chemotherapy.

Biomimetic Human Serum Albumin Nanoparticle for Efficiently Targeting Therapy to Metastatic Breast Cancers.

Preparation and characterization of paclitaxel palmitate albumin nanoparticles with high loading efficacy: an in vitro and in vivo anti-tumor study in mouse models

Discovery of a potent dual EGFR/HER-2 inhibitor L-2 (selatinib) for the treatment of cancer.

Reversing P-Glycoprotein-Associated Multidrug Resistance of Breast Cancer by Targeted Acid-Cleavable Polysaccharide Nanoparticles with Lapatinib Sensitization.